IDO1 and inflammatory bowel disease: Moreover, mucosal levels of IDO1 as well as systemic catalytic activity are significantly decreased in patients achieving endoscopic response at week 16, suggesting that IDO1 enzymatic activity may hold promise as biomarker for disease and treatment monitoring in IBD.